BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21814021)

  • 1. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporosis and RANKL signal].
    Nakamura M; Udagawa N
    Clin Calcium; 2011 Aug; 21(8):1149-55. PubMed ID: 21814019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutual interaction between myeloma cells and bone marrow microenvironment].
    Abe M
    Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
    [No Abstract]   [Full Text] [Related]  

  • 11. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Aug; 24(8):1159-68. PubMed ID: 25065867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RANKL/RANK signaling in rheumatoid arthritis].
    Omata Y; Tanaka S
    Clin Calcium; 2011 Aug; 21(8):1175-80. PubMed ID: 21814022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in bone biology and new treatments for bone loss.
    Gallagher JC
    Maturitas; 2008 May; 60(1):65-9. PubMed ID: 18555623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
    [No Abstract]   [Full Text] [Related]  

  • 18. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.